Results 161 to 170 of about 17,554 (214)

A self-nanoemulsifying drug delivery system for enhancing the oral bioavailability of candesartan cilexetil: Ex-vivo and in-vivo evaluation.

Journal of Pharmacy and Science, 2019
The drug delivery of candesartan cilexetil encounters obstacle of low absolute oral bioavailability which is attributed mainly to its low aqueous solubility and efflux by intestinal P-glycoprotein (P-gp) transporters.
K. AboulFotouh, Ayat A. Allam, M. El-Badry, A. M. El-Sayed   +3 more
semanticscholar   +1 more source

Antiviral activity of the FDA-approved drug candesartan cilexetil against Zika virus infection.

Antiviral Research, 2019
Zika virus (ZIKV) is a mosquito-borne virus that has risen to prominence as a significant threat to public health in the recent decade. Since its re-emergence in 2007, ZIKV has spread at an alarming rate and has since become endemic to multiple regions ...
Marcus Wing Choy Loe, Regina Ching Hua Lee, Chu Jang Hann Justin   +2 more
semanticscholar   +1 more source

Host-Guest Interactions between Candesartan and Its Prodrug Candesartan Cilexetil in Complex with 2-Hydroxypropyl-β-cyclodextrin: On the Biological Potency for Angiotensin II Antagonism.

Molecular Pharmaceutics, 2019
Renin-angiotensin aldosterone system inhibitors are for a long time extensively used for the treatment of cardiovascular and renal diseases. AT1 receptor blockers (ARBs or sartans) act as antihypertensive drugs by blocking the octapeptide hormone ...
Dimitrios Ntountaniotis, Ioannis Andreadelis, Tahsin F. Kellici, Vlasios Karageorgos, G. Leonis, E. Christodoulou, S. Kiriakidi, Johanna Becker‐Baldus, Evgenios K. Stylos, M. Chatziathanasiadou, C. Chatzigiannis, D. Damalas, B. Aksoydan, Uroš Javornik, G. Valsami, C. Glaubitz, S. Durdağı, N. Thomaidis, A. Kolocouris, J. Plavec, A. Tzakos, G. Liapakis, T. Mavromoustakos   +22 more
semanticscholar   +1 more source

Candesartan and epigallocatechin‐3‐gallate ameliorate gentamicin‐induced renal damage in rats through p38‐MAPK and NF‐κB pathways

Journal of biochemical and molecular toxicology, 2018
This study pointed to estimate the possible protective impacts of candesartan and/or epigallocatechin‐3‐gallate (EGCG) against gentamicin‐induced nephrotoxicity.
Hebatalla I. Ahmed, E. Mohamed
semanticscholar   +1 more source

Suppressive effects of type I angiotensin receptor antagonists, candesartan and irbesartan on allergic asthma

European Journal of Pharmacology, 2019
The effects of candesartan and irbesartan, antagonists of the type I angiotensin II receptor, were investigated on allergic asthma. The antigen‐induced degranulation was measured by evaluating &bgr;‐hexosaminidase activity in vitro.
Mi‐jeong Kim, D. Im
semanticscholar   +1 more source

Pleiotropic Benefits of the Angiotensin Receptor Blocker Candesartan in a Mouse Model of Alzheimer Disease

HYPERTENSION, 2018
The angiotensin receptor blocker losartan mitigated cerebrovascular and cognitive deficits in mouse models of Alzheimer disease, in line with some clinical evidence of reduced onset and progression to Alzheimer disease.
L. Trigiani, Jessika Royea, María Lacalle-Aurioles, X. Tong, E. Hamel   +4 more
semanticscholar   +1 more source

Antihypertensive drug‐candesartan attenuates TRAIL resistance in human lung cancer via AMPK‐mediated inhibition of autophagy flux

Experimental Cell Research, 2018
Angiotensin II type 1 receptor blockers (ARBs) are widely used as antihypertensive drugs. Candesartan is an ARB that has also been known for its anticancer effects but the exact molecular mechanism is remaining elusive.
Mohammad Rasheduzzaman, Sang-Youel Park
semanticscholar   +1 more source

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

The Lancet, 2003
S. Yusuf, M. Pfeffer, K. Swedberg, C. Granger, P. Held, J. McMurray, E. Michelson, B. Olofsson, J. Ostergren   +8 more
semanticscholar   +1 more source

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

The Lancet, 2003
J. McMurray, J. Ostergren, K. Swedberg, C. Granger, P. Held, E. Michelson, B. Olofsson, S. Yusuf, M. Pfeffer   +8 more
semanticscholar   +1 more source

Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients

Archives of pharmacal research, 2021
E. Jung, Chang-Keun Cho, Pureum Kang, Hye-Jung Park, Yun-Jeong Lee, J. Bae, Chang-ik Choi, C. Jang, Seok-Yong Lee   +8 more
semanticscholar   +1 more source